Our History

Medicure was founded in 1997 and became a public company in November 1999. As a U.S focused Specialty Pharma company with established sales of Aggrastat, Medicure carefully monitors opportunities within its own pipeline of products and possible strategic acquisitions in order to realize long-term value.

1997
- - Medicure Inc. founded
Pre-2003
- - MC-1 demonstrated potential in pre-clinical and Phase 1 studies
2003
- - MC-1 meets primary and secondary endpoint of Phase 2 MEND-1 Clinical Trial
2006
- - Positive results seen for MC-1 in MEND-CABG- 1 Phase 2 Trial meeting primary endpoint reducing CV death and MI by 37%
    
    Acquired full U.S. rights to Aggrastat^®
2008
- - MC-1 did not meet the primary endpoint in the MEND-CABG II Phase 3 trial, largely due to an unexpectedly low event rate in the placebo group compared to MEND-CABG I
2012
- - Agreement to promote Aggrastat^® in the Commonwealth of Puerto Rico
    
    Initiation of Aggrastat^® vs Integrilin^® in PCI clinical program
2013
- - FDA approval of Aggrastat High-Dose Bolus (HDB) regimen
2015
- - FDA approval of expanded dosing time for Aggrastat®
2016
- - Launch of Aggrastat^® Bolus Vial Format
    
    Acquired majority interest in Apicore
2017
- - FDA approval of Prexxartan^®
    
    Sale of Apicore Business
    
    FDA approval of Zypitamag™
2018
- - FDA approval of Sodium Nitroprusside Injection
    
    Entered into strategic collaboration with Cadila Healthcare Ltd
2019
- - Completion of Aggrastat^® vs Integrilin^® in PCI clinical program
    
    Completion of Aggrastat^® Phase IV clinical program enrollment
    
    Preferred pricing agreement with the AIDS Drug Assistance Program (ADAP) Crisis Task Force for Zypitamag
    
    Acquired full U.S. rights to Zypitamag
    
    Launch of ReDS™ PRO Heart Failure Device
    
    Entered into strategic collaboration with Sensible Medical
2020
- - Acquired Marley Drug specialty pharmacy
    
    Entered into strategic collaboration with Reliance Life Sciences
    
    Completion of Aggrastat^® Phase IV clinical program
2021
- - Completion of Aggrastat^® Phase 1/2a exploratory clinical program enrollment
    
    MC-1 Phase 3 clinical program IND filing with FDA
    
    Expansion of Marley Drug pharmacy formulary to include 100+ prescription medications
    
    Aggrastat^® vs Integrilin^® in PCI Phase 2 clinical study meets primary endpoint
2022
- - Launch of e-commerce pharmacy platform (www.marleydrug.com) through subsidiary, Marley Drug Pharmacy
2023
- - New partnership expands access to low-cost BRENZAVVY® (bexagliflozin) for U.S. patients through Marley Drug
    
    FDA provides complete approval to enroll patients in Phase 3 trial for MC-1 for treatment of rare pediatric disease
2024
- - Received U.S. FDA fast track designation for MC-1 for PNPO Deficiency
    
    Announced purchasing of intellectual property from CanAm Bioresearch
2025
- - Expansion of Pharmacy Business through Purchase of Gateway Medical Pharmacy
    
    Expansion of Pharmacy Business through Purchase of West Olympia Pharmacy

Stay Connected

Sign up for our newsletter